In malignant glioma and prostate cancer, avasimibe-mediated SOAT1 inhibition could elevate intracellular cholesterol content, consequently impeding SREBP1 activity and SREBP1-modulated fatty acids synthesis and uptake10,12. The gene discussed is SOAT1; the disease is Familial prostate cancer.